Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?

Abstract

BACKGROUND:

The current outbreak of pandemic coronavirus disease 2019 (COVID-19) aggravates serious need for effective therapeutics. Over recent years, drug repurposing has been accomplished as an important opportunity in drug development as it shortens the time consumed for development, besides sparing the cost and the efforts exerted in the research and development process. The FDA-approved antiparasitic drug, nitazoxanide (NTZ), has been found to have antiviral activity against different viral infections such as coronaviruses, influenza, hepatitis C virus (HCV), hepatitis B virus (HBV), and other viruses signifying its potential as a broad spectrum antiviral drug. Moreover, it has been recently reported that NTZ exhibited in vitro inhibition of SARS-CoV-2 at a small micromolar concentration. Additionally, NTZ suppresses the production of cytokines emphasizing its potential to manage COVID-19-induced cytokine storm. Furthermore, the reported efficacy of NTZ to bronchodilate the extremely contracted airways can be beneficial in alleviating COVID-19-associated symptoms.

SHORT CONCLUSION:

All these findings, along with the high safety record of the drug, have gained our interest to urge conductance of clinical trials to assess the potential benefits of using it in COVID-19 patients. Thus, in this summarized article, we review the antiviral activities of NTZ and highlight its promising therapeutic actions that make the drug worth clinical trials.

• Authors: Dina B Mahmoud, Zayyanu Shitu, Ahmed Mostafa
• Journal: Journal, genetic engineering & biotechnology (J Genet Eng Biotechnol) Vol. 18 Issue 1 Pg. 35 (Jul 28 2020) ISSN: 2090-5920 [Electronic] Netherlands
• PMID: 32725286 (Publication Type: Journal Article, Review)